| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Quebrachitol targets multiple signaling pathways involved in cell proliferation, differentiation, and bone formation. It promotes osteoblastogenesis by upregulating bone morphogenetic protein-2 (BMP-2) and runt-related transcription factor-2 (Runx2). Additionally, it activates the mitogen-activated protein kinase (MAPK) pathway, specifically ERK, JNK, and p38α, as well as the Wnt/β-catenin signaling pathway. It also down-regulates the receptor activator of nuclear factor-κB ligand (RANKL) mRNA level, which is involved in osteoclast differentiation. Thus, its primary targets are the BMP-2/Runx2/MAPK/Wnt/β-catenin signaling axes.
|
|---|---|
| ln Vitro |
In vitro, Quebrachitol significantly promotes the proliferation and DNA synthesis of MC3T3-E1 osteoblast precursor cells. It enhances the differentiation and mineralization of these cells, as evidenced by increased alkaline phosphatase activity and mineralized nodule formation. The compound's activity is mediated through the upregulation of BMP-2, Runx2, and the activation of MAPK and Wnt/β-catenin pathways. Furthermore, Quebrachitol exhibits free-radical scavenging activity and has been shown to improve glucose and lipid metabolism in insulin-resistant HepG2 cells.
|
| ln Vivo |
In vivo, Quebrachitol has demonstrated bone mineral density enhancing effects in animal models. Studies have shown that it can promote bone formation and increase bone mass, suggesting its potential for treating osteoporosis and other bone-related disorders. Its gastroprotective and anti-diabetic activities have also been observed in vivo, although specific detailed in vivo efficacy data is limited in the provided search results.
|
| Enzyme Assay |
The in vitro activity of Quebrachitol is typically assessed using cell-free enzyme activity assays and signaling pathway analysis. For instance, the activation of MAPK (ERK, JNK, p38α) can be measured by Western blotting using phospho-specific antibodies against these kinases. Wnt/β-catenin signaling can be evaluated by measuring β-catenin protein levels or using a TCF/LEF reporter gene assay. These assays involve incubating cell lysates or purified proteins with specific substrates and detecting the products using spectrophotometric, chemiluminescent, or fluorescent methods.
|
| Cell Assay |
For cellular assays, MC3T3-E1 mouse osteoblast precursor cells are commonly used. Cells are cultured in alpha-minimum essential medium (α-MEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. They are then treated with various concentrations of Quebrachitol (typically ranging from 1 to 100 µM) for different time periods (e.g., 24-72 hours). Cell proliferation is assessed using the MTT or CCK-8 assay, while differentiation is evaluated by measuring alkaline phosphatase (ALP) activity and mineralization via Alizarin Red S staining. Gene expression of BMP-2, Runx2, and other osteogenic markers is analyzed by quantitative real-time PCR.
|
| Animal Protocol |
In vivo, Quebrachitol is typically administered orally to animal models, such as ovariectomized (OVX) rats, which serve as a model for postmenopausal osteoporosis. The compound is dissolved in a suitable vehicle (e.g., saline or carboxymethyl cellulose) and given at doses ranging from 10 to 100 mg/kg body weight daily for several weeks. Bone mineral density is measured using dual-energy X-ray absorptiometry (DXA) or micro-computed tomography (micro-CT). Serum markers of bone formation (e.g., osteocalcin) and bone resorption (e.g., C-telopeptide) are also analyzed to assess the compound's effect on bone metabolism.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic (PK) parameters for Quebrachitol are not detailed in the provided search results. As a naturally occurring polyol with a molecular weight of 194.18 g/mol, it is expected to be water-soluble and orally bioavailable. Its absorption, distribution, metabolism, and excretion (ADME) profile would likely follow that of similar small, hydrophilic molecules. Further detailed PK studies are needed to fully characterize its bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Quebrachitol is not available in the provided search results. However, as a natural product found in various plants and used in traditional medicine, it is generally considered to have a low toxicity profile. In in vitro studies using MC3T3-E1 cells, Quebrachitol did not exhibit significant cytotoxicity at concentrations up to 100 µM, indicating a favorable safety window for its osteogenic effects. Comprehensive toxicological studies, including acute and chronic toxicity assessments, are required to establish its full safety profile.
|
| References | |
| Additional Infomation |
L-Quibrazyl alcohol is a cyclohexanol compound. It has been reported to exist in Artemisia griseus, Mandevilla argentea, and other organisms for which relevant data are available.
Quebrachitol is a naturally occurring compound with promising potential in bone health, metabolic disorders, and as an antioxidant. Its mechanism of action involves the simultaneous activation of multiple osteogenic signaling pathways (BMP-2/Runx2/MAPK/Wnt/β-catenin), making it a unique natural product for osteoporosis research. It has not been approved by the FDA for clinical use and is currently only available for research purposes. Its presence in sea buckthorn and other plants also makes it a subject of interest in nutritional and functional food research. |
| Molecular Formula |
C7H14O6
|
|---|---|
| Molecular Weight |
194.1825
|
| Exact Mass |
194.079
|
| CAS # |
642-38-6
|
| PubChem CID |
151108
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
317.2±42.0 °C at 760 mmHg
|
| Melting Point |
189 - 192ºC
|
| Flash Point |
145.6±27.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
-0.74
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1[C@@H]([C@H](C([C@@H]([C@H]1O)O)O)O)O
|
| InChi Key |
DSCFFEYYQKSRSV-MBXCVVGISA-N
|
| InChi Code |
InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5+,6+,7?/m0/s1
|
| Chemical Name |
(1R,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~643.73 mM)
H2O : ~100 mg/mL (~514.99 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
